Home > Publications database > Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma. > print |
001 | 127124 | ||
005 | 20240228140907.0 | ||
024 | 7 | _ | |a 10.1158/1078-0432.CCR-14-1029 |2 doi |
024 | 7 | _ | |a pmid:25351744 |2 pmid |
024 | 7 | _ | |a 1078-0432 |2 ISSN |
024 | 7 | _ | |a 1557-3265 |2 ISSN |
024 | 7 | _ | |a altmetric:2820486 |2 altmetric |
037 | _ | _ | |a DKFZ-2017-03150 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Merz, Maximilian |0 P:(DE-HGF)0 |b 0 |e First author |
245 | _ | _ | |a Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma. |
260 | _ | _ | |a Philadelphia, Pa. [u.a.] |c 2015 |b AACR |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1522328397_8698 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a To noninvasively assess bone marrow microcirculation before and after therapy in patients with newly diagnosed multiple myeloma with dynamic contrast-enhanced MRI (DCE-MRI).Ninety-six patients received DCE-MRI before and after primary treatment for newly diagnosed multiple myeloma. For the 91 evaluable patients, treatment consisted of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in 82 patients and chemotherapy without ASCT in 9 patients. In addition, 33 healthy volunteers were imaged as the control group. Analysis of DCE-MRI was performed according to the two-compartment model by Brix to quantify amplitude A (associated with blood volume) and exchange rate constant kep (reflecting vessel permeability and perfusion).Nonresponders showed significantly higher A-values before the start of therapy compared with responders (P = 0.02). In both responders and nonresponders to therapy, A-values dropped significantly (P = 0.004 and <0.001, respectively) after primary therapy, whereas lower values for kep were found only in responders (P < 0.001). Depth of remission was significantly correlated to decreased bone marrow microcirculation: Patients in near complete response (nCR) or complete remission (CR) after treatment showed significantly lower values for A compared with patients not achieving nCR+CR. The application of HDT or novel agents had no significant effect on DCE-MRI parameters after therapy, although patients treated with novel agents more often achieved nCR+CR (42%/12.5%; P < 0.002). Higher kep-values at second MRI were positively correlated to shorter overall survival (HR 3.53; 95% confidence intervals, 1.21-10.33; P = 0.02).Parameters from DCE-MRI are correlated to remission after primary therapy and outcome in newly diagnosed multiple myeloma. |
536 | _ | _ | |a 315 - Imaging and radiooncology (POF3-315) |0 G:(DE-HGF)POF3-315 |c POF3-315 |f POF III |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
650 | _ | 7 | |a Angiogenesis Inhibitors |2 NLM Chemicals |
700 | 1 | _ | |a Ritsch, Judith |b 1 |
700 | 1 | _ | |a Kunz, Christina |0 P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2 |b 2 |u dkfz |
700 | 1 | _ | |a Wagner, Barbara |b 3 |
700 | 1 | _ | |a Sauer, Sandra |b 4 |
700 | 1 | _ | |a Hose, Dirk |b 5 |
700 | 1 | _ | |a Moehler, Thomas |b 6 |
700 | 1 | _ | |a Delorme, Stefan |0 P:(DE-He78)3e76653311420a51a5faeb80363bd73e |b 7 |u dkfz |
700 | 1 | _ | |a Goldschmidt, Hartmut |b 8 |
700 | 1 | _ | |a Zechmann, Christian |b 9 |
700 | 1 | _ | |a Hillengass, Jens |0 P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5 |b 10 |e Last author |u dkfz |
773 | _ | _ | |a 10.1158/1078-0432.CCR-14-1029 |g Vol. 21, no. 1, p. 106 - 112 |0 PERI:(DE-600)2036787-9 |n 1 |p 106 - 112 |t Clinical cancer research |v 21 |y 2015 |x 1557-3265 |
909 | C | O | |o oai:inrepo02.dkfz.de:127124 |p VDB |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)3e76653311420a51a5faeb80363bd73e |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5 |
913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |2 G:(DE-HGF)POF3-300 |v Imaging and radiooncology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
914 | 1 | _ | |y 2015 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN CANCER RES : 2015 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CLIN CANCER RES : 2015 |
920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l Radiologie |x 0 |
920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 1 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)E010-20160331 |
980 | _ | _ | |a I:(DE-He78)C060-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|